Cardiovascular mortality is a major cause of death among in type 2 diabetes (T2DM).
Endothelial dysfunction (ED) is a well-known important risk factor for the development of …

Cardiovascular and metabolic diseases remain the leading cause of morbidity and mortality
worldwide. Endothelial dysfunction is a key player in the initiation and progression of …

As a first-line treatment for diabetes, the insulin-sensitizing biguanide, metformin, regulates
glucose levels and positively affects cardiovascular function in patients with diabetes and …

Metformin has been used in diabetes for more than 60 years and has excellent safety in the
therapy of human type 2 diabetes (T2D). There is growing evidence that the beneficial …

Cardiovascular events occurring in type 2 diabetes (T2DM) are a major problem in clinical
practice. In particular, the risk of myocardial infarction (MI) presented by patients affected by …

Atherosclerosis is a common cause of cardiovascular disease, which, in turn, is often fatal.
Today, we know a lot about the pathogenesis of atherosclerosis. However, the main …

Aims Several studies have investigated the effects of metformin treatment in patients with
type 1 diabetes mellitus (T1DM). No study has hitherto examined its effects on endothelial …

Metformin, a well‐known AMPK agonist, has been widely used as the first‐line drug for
treating type 2 diabetes. There had been a significant concern regarding the use of …

Introduction: Metformin is a widely used drug in the treatment of type 2 diabetes mellitus
(T2DM). However, it is becoming an attractive drug to manage patients with pre-diabetes …

Since metformin can exert beneficial vascular effects, we aimed at studying its effect on
reactive oxygen species (ROS) production, antioxidant enzyme expression, levels of …